nach oben

Drugs

Erschienen in:

01.06.2006 | Therapy in Practice

Pharmacotherapy of Lupus Nephritis in Children

A Recommended Treatment Approach

verfasst von: Alexa Adams, Emma Jane MacDermott, Dr Thomas J. A. Lehman

Erschienen in: Drugs | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease of unknown aetiology, which is characterised by recurrent disease flares that may affect any organ system. Renal involvement remains one of the chief causes of morbidity and mortality in children with lupus. Nephritis occurs in approximately two-thirds of patients, ranging from mild glomerulitis to life-threatening occurrences of diffuse proliferative glomerulonephritis. As lupus nephritis is a condition of no single aetiology, there is no single cure. Corticosteroids, although still the first line of treatment, are increasingly being superseded by cytotoxic drugs, in particular cyclophosphamide and corticosteroid-sparing agents. Newer agents such as mycophenolate mofetil, although effective in the treatment of lupus in adults, are less effective in children. Standard of care for highly active lupus nephritis in children remains intravenous cyclophosphamide, although preliminary experience suggests that the addition of rituximab may allow for remission induction with a reduction in cumulative cyclophosphamide dose. Combination therapies and newer agents appear promising for the future as our understanding of the immune system and its dysregulation in SLE improves. In this review, we discuss the current standards of care, newer therapies currently in use, and emerging treatments still undergoing development and investigation. We conclude by discussing our guidelines for treatment at the present time and suggestions for the comprehensive care of children with lupus nephritis.

Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 4th ed. Philadelphia (PA): WB Saunders Company, 2001

Hochberg M. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970–1977. Arthritis Rheum 1985; 28: 80–6PubMedCrossRef

Siegel M, Lee ML. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 1973; 3: 1–54PubMedCrossRef

Lehman TJA, McCurdy DK, Bernstein BH, et al. Systemic lupus in the first decade of life. Pediatrics 1989 Feb; 83(2): 235–9PubMed

Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994; 8: 230–49PubMedCrossRef

McCurdy DK, Lehman TJ, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992; 89(2): 240–6PubMed

Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002 Dec; 29(12): 2635–42PubMed

Spahn JD, Kamada AK. Special considerations in the use of glucocorticoids in children. Pediatr Rev 1995; 16: 266–72PubMedCrossRef

Satel SL. Mental status changes in children receiving glucocorticoids. Clin Pediatr (Phila) 1990; 29: 382–8CrossRef

10.

Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113: 249–54PubMedCrossRef

11.

Loeb JN. Corticosteroids and growth. N Engl J Med 1976; 295: 547–52PubMedCrossRef

12.

McCarthy TL, Centrella M, Canalis E. Cortisol inhibits the synthesis of insulin-like growth factor 1 in skeletal cells. Endocrinology 1990; 126: 1569–75PubMedCrossRef

13.

Lehman TJA, Mouradian JA. Systemic lupus erythematosus. In: Holliday M, Barratt M, Avner ED, editors. Pediatric nephrology. 4th ed. Baltimore (MD): William and Wilkins, 1999

14.

Ilowite NT, Samuel P, Ginzler E, et al. Dyslipoprotienemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988 Jul; 31(7): 859–63PubMedCrossRef

15.

Ilowite NT. Premature Atherosclerosis in systemic lupus erythematosus. J Rheumatol Suppl 2000 Apr; 58: 15–9PubMed

16.

Barron KS, Person DA, Brewer EJ, et al. Pulse methylprednisolne therapy in diffuse proliferative lupus nephritis. J Pediatr 1982 Jul; 101(1): 137–41PubMedCrossRef

17.

Garin EH, Sleasman JW, Richard GA, et al. Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. Eur J Pediatr 1986 Oct; 145(5): 380–3PubMedCrossRef

18.

Lehman TJ, Sherry DD, Wagner-Weiner L, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989 Jun; 114(6): 1055–60PubMedCrossRef

19.

Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000 Feb; 136(2): 243–7PubMedCrossRef

20.

Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004; 63: 321–3PubMedCrossRef

21.

Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003 Jun; 48(6): 1484–92PubMedCrossRef

22.

Looney RJ, Anolik JH, Campbell D, et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose escalation trial of Rituximab. Arthritis Rheum 2004 Aug; 50(8): 2580–9PubMedCrossRef

23.

Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down regulation of the T-cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum 2005; 52(2): 501–13PubMedCrossRef

24.

Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17: 550–7PubMedCrossRef

25.

Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus ertheymatosus. Arthrtis Rheum 2004; 50(11): 3580–90CrossRef

26.

Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52(10): 3168–74PubMedCrossRef

27.

McCune WJ, Riskalla MM. Mycophenolate mofetil: a magic bullet for lupus? J Rheum 2005 Jun; 32(6): 1047–52

28.

Kimball JA, Pescovitz MD, Book BK, et al. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995 Dec; 60(2): 1379–83PubMedCrossRef

29.

Raab M, Daxecker H, Pavlovic V, et al. Quantification of the influence of mycophenolic acid on the release of endothelial adhesion molecules. Clin Chim Acta 2002 Jun; 320(1–2): 89–4PubMedCrossRef

30.

Lui SL, Tsang R, Wong D, et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11(7): 411–8PubMedCrossRef

31.

Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004 Jun; 77(11): 1661–7PubMedCrossRef

32.

Ginzler EMAC, Buyon J, Dooley MA, et al. A multicenter study of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN); preliminary results [abstract]. Arthritis Rheum 2003; 48 Suppl.: S647

33.

Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115: 705–9

34.

Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–80PubMedCrossRef

35.

Fu YF, Lu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001 Apr; 55(4): 318–21PubMed

36.

Buratti S, Szer S, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001 Sep; 28(9): 2103–8PubMed

37.

Fu LW, Yang LY, Chan WP, et al. Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephrtitis with heavy proteinuria. Br J Rheumatol 1998; 37: 217–21PubMedCrossRef

38.

Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969–74PubMedCrossRef

39.

Kalunian KC, Davis JC, Merrill JT, et al. IDEC-131 Lupus study group. Treatment of systemic lupus erythematosus by inhibition of T cell co-stimulation with antiCD154: a randomised double-blind, placebo controlled trial. Arthritis Rheum 2002; 46: 3251–8

40.

Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40-ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719–27PubMedCrossRef

41.

Finck B, Linsley P, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225–7PubMedCrossRef

42.

Hervey PS, Keam SJ. Abatacept. BioDrugs 2006; 20(1): 53–62PubMedCrossRef

43.

Tahir H, Isenberg DA. Novel therapies in lupus nephritis. Lupus 2005; 14: 77–82PubMedCrossRef

44.

Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus 2005; 14: 189–91PubMedCrossRef

45.

Stohl W. A therapeutic role for BLys. Lupus 2004; 13: 317–22PubMedCrossRef

46.

Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLys (B lymphocyte stimulator) protein. Curr Opin Rheumatol 2002; 14: 522–8PubMedCrossRef

47.

Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003 Jan; 48(1): 166–7322PubMedCrossRef

48.

Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus nephritis. J Nephrol 2003; 16: 787–91PubMed

49.

Stone JH, Millward CL, Olson JL, et al. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998; 41: 678–86PubMedCrossRef

50.

Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003; 75: 651–6PubMedCrossRef

51.

Ponticelli C, Moroni G. Renal transplantation in lupus nephritis. Lupus 2005; 14: 95–8PubMedCrossRef

52.

Ilei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248–57

53.

Rudge S, Hailwood S, Home A, et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 2005; 44: 813–8PubMedCrossRef

Titel: Pharmacotherapy of Lupus Nephritis in Children
A Recommended Treatment Approach
verfasst von: Alexa Adams
Emma Jane MacDermott
Dr Thomas J. A. Lehman
Publikationsdatum: 01.06.2006
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 9/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666090-00003

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pharmacotherapy of Lupus Nephritis in Children

A Recommended Treatment Approach

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2006

Pharmacological Therapy for Wegener’s Granulomatosis

Desirable Therapeutic Characteristics of an Optimal Antihypertensive Agent

Pharmacotherapy of Alcoholism in Patients with Co-morbid Psychiatric Disorders

Probiotics for Prevention of Recurrent Urinary Tract Infections in Women

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)

ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus